Description
With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.
For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:
- Stem Cell Therapeutics (Transplantation)
- Cord Blood Banking and
- Drug development
This report breaks down forecasted revenues and procedure volumes for stem cell technologies for these segments in the following disease areas:
- Cardiovascular disease
- Lung disease
- Arthritis
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Orthopedics
- Infertility
- Alzheimer’s disease
- Burns (severe)
- Lupus
- Parkinson’s disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Crohn’s disease
- Sickle cell disease
- Multiple myeloma
- NH lymphoma
- Leukemia
Ths report is the result of exclusive interviews with executives in the stem cell industry, a review of medical and company literature, government databases and publications. As part of this comprehensive analysis of stem cell markets, the following companies were profiled:
- Aastrom Biosciences
- Advanced Cell Technologies
- Brainstorm Cell Therapeutics
- Celegene
- Cord Blood America
- Cord Blood Registry
- Cryo-Cell International
- ES Cell International
- Geron
- Harvest Technologies
- Invitrogen
- Medistem
- Neostem
- Opexa Therapeutics
- Osiris Therapeutics
- Plureon
- Regenetech
- Revivicor
- Stem Cell Sciences
- StemLifeLine
- ThermoGenesis
- VetCell Bioscience
- ViaCell
License Note: Kalorama Information’s listed default price on its information products reflects a single user license only. Purchasing a departmental license (up to 10 users at one location) or a global site license (entire company) permits multiple individuals in the company to benefit from this resource.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Introduction
- Current Stem Cell Therapies
- Developmental Stem Cell Therapies
- Issues in Stem Cell Research
- Embryonic Stem Cells
- Non-Embryonic Stem Cells
- Stem Cell Forecasts
CHAPTER TWO: INTRODUCTION
- The Promise of Stem Cells in Medical Treatment
- Types of Stem Cells
- Embryonic Stem Cells
- Important Developments in ES Cell Research
- Adult Stem Cells
- Important Developments in AS Cell Research
- Cord Blood Stem Cells
- Stem Cell Harvesting
- Embryonic Stem Cells
- Unfertilized Eggs
- Adult Stem Cells
- Leukapheresis
- Peripheral Blood
- Cord Blood Stem Cells
- Transplantation Approaches
- Allogenic Transplantation
- Transplantation Procedures
- Cancerous Stem Cells
- Stem Cells in Drug Development
- Stem Cell Therapeutics
- Stem Cell Targeting Drugs
- Stem Cell Generated Organs
CHAPTER THREE: CURRENT STEM CELL THERAPIES
- Cancer
- Leukemia
- Gene Therapy
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Noncancerous Diseases
- Aplastic Anemia
- Immunodeficiency
- Lupus
- Sickle Cell Disease
- Other Conditions
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
- Stem Cells in Alzheimer’s Disease
- Stem Cells in Arthritis
- Stem Cells in Burns
- Stem Cells in Cancer
- Stem Cells in Cardiovascular Conditions
- Stem Cells in Critical Limb Ischemia
- Stem Cells in Crohn’s Disease
- Stem Cells in Diabetes
- Stem Cells in Incontinence
- Stem Cells in Infertility
- Stem Cells in Liver Failure
- Stem Cells in Lung Disease
- Stem Cells in Multiple Sclerosis
- Stem Cells in Orthopedics
- Stem Cells in Osteoporosis
- Stem Cells in Parkinson’s Disease
- Stem Cells in Sickle Cell Disease
- Stem Cells in Best Case
- Stem Cell Therapeutics
- Fees Related to Drug Development
- Most Likely Case
- Stem Cell Therapeutics
- Fees Related to Drug Development
- Worst Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
CHAPTER FIVE: MARKET ANALYSIS
CHAPTER SIX: ISSUES IN STEM CELL RESEARCH
- Ethical Questions
- Research Funding
- Federal Funding
- State Funding
- International Initiatives
- Stem Cell Patents
CHAPTER SEVEN: COMPANY PROFILES
- Aastrom Biosciences
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Advanced Cell Technologies
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Brainstorm Cell Therapeutics
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Celegene
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Cord Blood America
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Cord Blood Registry
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Cryo-Cell International
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- ES Cell International
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Geron
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Harvest Technologies
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Invitrogen
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Medistem
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Neostem
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Opexa Therapeutics
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Osiris Therapeutics
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Plureon
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Regenetech
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- Revivicor
- History and Lines of Business
- Financial Information
- Stem Cell Sciences
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- StemLifeLine
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- ThermoGenesis
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- VetCell Bioscience
- History and Lines of Business
- Financial Information
- Stem Cell Technology
- ViaCell
- History and Lines of Business
- Financial Information
- Stem Cell Technology
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Total Market for Stem Cell Technologies in $ Millions, 2007-2020
- Table 1-2: Stem Cell Therapeutics Market in $ Millions, 2007-2020
- Table 1-3: Total Market for Cord Blood Banking Fees in $ Millions, 2007-2020
- Table 1-4: Total Market for Stem Cell Drug Development Technologies in $ Millions, 2007-2020
CHAPTER THREE: CURRENT STEM CELL THERAPIES
- Table 3-1: Types of Leukemia, 2007
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
- Table 4-1: Global Disease Populations Addressed by Potential Stem Cell Therapies, 2007
- Table 4-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Table 4-3: Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2007 and 2020
- Table 4-4: Types and Features of Urinary Incontinence, 2007
- Table 4-5: Types and Causes of Male Infertility, 2007
- Table 4-6: Common Diseases of the Lungs, 2007
CHAPTER FIVE: MARKET ANALYSIS
- Table 5-1: Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2007
- Table 5-2: Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020
- Table 5-3: Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007 – 2020
- Table 5-4: Best Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
- Table 5-5: Best Case: Stem Cell-Based Drug Development Technology Fees, 2007-2020 (Preclinical Drug Candidates, Cost of Testing, Utilization of New Technology, Cost of New Technolgy per Drug)
- Table 5-6: Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
- Table 5-7: Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020
- Table 5-8: Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
- Table 5-9: Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2007-2020
- Table 5-10: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
- Table 5-11: Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
- Table 5-12: Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2007 – 2020
- Table 5-13: Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2007-2020
- Table 5-15: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
- Table 5-16: Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2007-2020
ISSUES IN STEM CELL RESEARCH
- Table 6-1: NIH Funding for Stem Cell Research in $ Million, 2003-2008 (est.)
- Table 6-2: Positions on Human ES Cell Research by Country, 2007
COMPANY PROFILES
- Table 7-1: Main Activities of Selected Stem Cell Companies, 2007
- Table 7-2: Therapeutic Focus of Selected Stem Cell Therapeutics Companies, 2007
